Top

Cancer Immunology, Immunotherapy

Published in:

01-10-2017 | Original Article

Decreased human leukocyte antigen A*02:01 frequency is associated with risk of glioma and existence of human cytomegalovirus: a case–control study in Northern China

Authors: Sheng Han, Jian Deng, Zixun Wang, Huan Liu, Wen Cheng, Anhua Wu

Published in: Cancer Immunology, Immunotherapy | Issue 10/2017

Abstract

Background

Human leukocyte antigens (HLAs) play an important role in host defense against viral infection and tumorigenesis. Human cytomegalovirus (HCMV) has been linked to glioma development. This study investigated the relationship between HLA distribution, presence of HCMV, and glioma development in a Han Chinese population.

Methods

The study population included 150 glioma patients and 150 tumor-free brain injury control subjects (control-A) matched according to geography, ethnicity, age, and gender. HLA allele frequency was compared between the two groups using peripheral blood samples by PCR sequence-based typing. These data were also compared with HLA frequencies obtained from a Northern Chinese Han population database (control-B). HCMV DNA was detected in the peripheral blood of glioma patients and control group-A by nested PCR. The expression of HCMV proteins IE1-72 and pp65 in tumor tissues was evaluated by immunohistochemistry.

Results

The frequency of HLA-A*02:01 was decreased in glioma patients as compared to control group-A and -B (P < 0.001 and P = 0.001, respectively). The age/sex-adjusted odds ratio for HLA-A*02:01 positivity vs. negativity was 0.392 (95% confidence interval 0.225–0.683). HCMV was more frequently detected in the peripheral blood and tumor tissue of HLA-A*02:01-negative glioma patients. HLA-A*02:01 and HCMV were not associated with overall survival.

Conclusion

There is a correlation between decreased HLA-A*0201 allele frequency and glioma susceptibility.

Available only for authorised users

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed

Baumgarten P, Michaelis M, Rothweiler F, Starzetz T, Rabenau HF et al (2014) Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics. Neuro Oncol 16:1469–1477CrossRefPubMedPubMedCentral

Strong MJ, Blanchard E 4th, Lin Z, Morris CA, Baddoo M et al (2016) A comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus—tumor association. Acta Neuropathol Commun 4:71CrossRefPubMedPubMedCentral

Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A et al (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10:10–18CrossRefPubMedPubMedCentral

Ding D, Han S, Wang Z, Guo Z, Wu A (2014) Does the existence of HCMV components predict poor prognosis in glioma. J Neurooncol 116:515–522CrossRefPubMed

Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor DSR et al (2012) Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol 14:246–255CrossRefPubMedPubMedCentral

Mohammad AA, Rahbar A, Lui WO, Davoudi B, Catrina A et al (2014) Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls. PLoS One 9:e113740CrossRefPubMedPubMedCentral

dos Santos CJ, Stangherlin LM, Figueiredo EG, Correa C, Teixeira MJ, da Silva MC (2014) High prevalence of HCMV and viral load in tumor tissues and peripheral blood of glioblastoma multiforme patients. J Med Virol 86:1953–1961CrossRefPubMed

Fajfr M, Stepanova V (2013) Cytomegalovirus and its relationship to chronic inflammatory bowel diseases and tumors. Klin Mikrobiol Infekc Lek 19:103–106PubMed

10.

Cobbs CS (2013) Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol 25:682–688CrossRefPubMed

11.

Price RL, Song J, Bingmer K, Kim TH, Yi JY et al (2013) Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res 73:3441–3450CrossRefPubMedPubMedCentral

12.

Zhang HG, Pang XW, Shang XY, Xing Q, Chen WF (2003) Functional supertype of HLA-A2 in the presentation of Flu matrix p58–66 to induce CD8+ T-cell response in a Northern Chinese population. Tissue Antigens 62:285–295CrossRefPubMed

13.

La Torre D, Maugeri R, Angileri FF, Pezzino G, Conti A et al (2009) Human leukocyte antigen frequency in human high-grade gliomas: a case–control study in Sicily. Neurosurgery 64:1082–1088 (discussion 1088–1089) CrossRefPubMed

14.

Hou TY, Chen HC, Chen CH, Chang DM, Liu FC, Lai JH (2007) Usefulness of human leucocyte antigen-B27 subtypes in predicting ankylosing spondylitis: Taiwan experience. Intern Med J 37:749–752PubMed

15.

Ballerini C, Guerini FR, Rombola G, Rosati E, Massacesi L et al (2004) HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe. J Neuroimmunol 150:178–185CrossRefPubMed

16.

Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH (2002) Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 31:355–360CrossRefPubMed

17.

Luongo V, Pirozzi G, Caraco C, Errico S, de Angelis F et al (2004) HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens 64:84–87CrossRefPubMed

18.

Ohtani M, Azuma T, Yamazaki S, Yamakawa A, Ito Y et al (2003) Association of the HLA-DRB1 gene locus with gastric adenocarcinoma in Japan. Dig Liver Dis 35:468–472CrossRefPubMed

19.

Younger AR, Amria S, Jeffrey WA, Mahdy AE, Goldstein OG et al (2008) HLA class II antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis 11:334–341CrossRefPubMed

20.

Song W, Ruder AM, Hu L, Li Y, Ni R et al (2009) Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs. PLoS One 4:e7157CrossRefPubMedPubMedCentral

21.

Guerini FR, Agliardi C, Zanzottera M, Delbue S, Pagani E et al (2006) Human leukocyte antigen distribution analysis in North Italian brain Glioma patients: an association with HLA-DRB1*14. J Neurooncol 77:213–217CrossRefPubMed

22.

Tang J, Shao W, Dorak MT, Li Y, Miike R et al (2005) Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomark Prev 14:2040–2044CrossRef

23.

Bassig BA, Inskip PD, Burdette L, Shapiro WR, Selker RG et al (2011) Selected human leukocyte antigen class II polymorphisms and risk of adult glioma. J Neuroimmunol 233:185–191CrossRefPubMed

24.

Krausa P, Brywka M 3rd, Savage D, Hui KM, Bunce M et al (1995) Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 45:223–231CrossRefPubMed

25.

Liang B, Zhu L, Liang Z, Weng X, Lu X et al (2006) A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell Mol Immunol 3:453–458PubMed

26.

Yang G, Deng YJ, Hu SN, Wu DY, Li SB et al (2006) HLA-A, -B, and -DRB1 polymorphism defined by sequence-based typing of the Han population in Northern China. Tissue Antigens 67:146–152CrossRefPubMed

27.

Deng Z, Wang D, Xu Y, Gao S, Zhou H et al (2010) HLA-C polymorphisms and PCR dropout in exons 2 and 3 of the Cw*0706 allele in sequence-based typing for unrelated Chinese marrow donors. Hum Immunol 71:577–581CrossRefPubMed

28.

Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R (2008) Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116:79–86CrossRefPubMedPubMedCentral

29.

Cobbs CS, Matlaf L, Harkins LE (2014) Methods for the detection of cytomegalovirus in glioblastoma cells and tissues. Methods Mol Biol 1119:165–196CrossRefPubMed

30.

Sjostrom S, Hjalmars U, Juto P, Wadell G, Hallmans G et al (2011) Human immunoglobulin G levels of viruses and associated glioma risk. Cancer Causes Control 22:1259–1266CrossRefPubMedPubMedCentral

31.

Amirian ES, Marquez-Do D, Bondy ML, Scheurer ME (2013) Anti-human-cytomegalovirus immunoglobulin G levels in glioma risk and prognosis. Cancer Med 2:57–62CrossRefPubMed

32.

Soroceanu L, Cobbs CS (2011) Is HCMV a tumor promoter. Virus Res 157:193–203CrossRefPubMed

33.

Hambardzumyan D, Gutmann DH, Kettenmann H (2016) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19:20–27CrossRefPubMedPubMedCentral

34.

Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (2002) Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8:2851–2855PubMed

35.

Ji J, Judkowski VA, Liu G, Wang H, Bunying A et al (2014) Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy. Stem Cells Transl Med 3:356–364CrossRefPubMed

36.

Myers CE, Hanavan P, Antwi K, Mahadevan D, Nadeem AJ et al (2011) CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells. Cancer Immunol Immunother 60:1319–1332CrossRefPubMed

37.

Frigerio S, Ciusani E, Pozzi A, Silvani A, Salmaggi A, Boiardi A (1999) Tumor necrosis factor microsatellite polymorphisms in Italian glioblastoma patients. Cancer Genet Cytogenet 109:172–174CrossRefPubMed

38.

Li R, Zhao Y, Fan W, Chen H, Chen Y et al (2011) Possible association between polymorphisms of human vascular endothelial growth factor A gene and susceptibility to glioma in a Chinese population. Int J Cancer 128:166–175CrossRefPubMed

39.

Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G et al (2009) High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res 7:665–677CrossRefPubMed

40.

Tenan M, Carrara F, DiDonato S, Finocchiaro G (1995) Absence of mutations and identification of two polymorphisms in the SSCP and sequence analysis of p21CKI gene in malignant gliomas. Int J Cancer 62:115–117CrossRefPubMed

41.

Tussey LG, Matsui M, Rowland-Jones S, Warburton R, Frelinger JA, McMichael A (1994) Analysis of mutant HLA-A2 molecules. Differential effects on peptide binding and CTL recognition. J Immunol 152:1213–1221PubMed

42.

Zou Y, Bresnahan W, Taylor RT, Stastny P (2005) Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol 174:3098–3104CrossRefPubMed

43.

Prins RM, Cloughesy TF, Liau LM (2008) Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359:539–541CrossRefPubMedPubMedCentral

44.

Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S et al (2014) Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res 74:3466–3476CrossRefPubMed

45.

Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C et al (2013) Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer 133:1204–1213CrossRefPubMed

Title: Decreased human leukocyte antigen A*02:01 frequency is associated with risk of glioma and existence of human cytomegalovirus: a case–control study in Northern China
Authors: Sheng Han
Jian Deng
Zixun Wang
Huan Liu
Wen Cheng
Anhua Wu
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 10/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-2018-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2017

Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy

A gene polymorphism in PD-L1 promoter region is not associated with PD-L1 expression and patients’ survival in gastric cancer

Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions

Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer

CD45RA−Foxp3high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma

In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer